OctoPlus signs drug development contract with The Medicines Company
13-Jul-2010
- Netherlands
Under the contract terms, OctoPlus will perform process development and clinical manufacturing for The Medicines Company related to MDCO-216 (ApoA-I Milano/phospholipid complex).
Most read news
Organizations
OctoPlus
Medicines Company
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Argenes Initiates Phase I Clinical Study of ARG098 (anti-Fas IgM monoclonal antibody) for Rheumatoid Arthritis in Europe
Go to page
Synthon opens state-of-the-art laboratory for biotechnology
Go to page
Amylin Pharmaceuticals Withdraws Swiss Regulatory Application for SYMLIN(R)
Go to page
Amiodarone
Go to page
Chlorhexidine
Go to page
Benzatropine
Go to page
OncoMethylome Sciences to Perform MGMT Testing in Roche Phase III Study of Avastin for Glioblastoma - OncoMethylome's Technology is being used in Roche Clinical Trial Program with Avastin
Go to page